TITLE

Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE

AUTHOR(S)
Abdwani, R.; Mani, R.
PUB. DATE
May 2009
SOURCE
Lupus;May2009, Vol. 18 Issue 5, p460
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Haematological involvement occurs frequently in childhood onset systemic lupus erythematosus (SLE) with autoimmune haemolytic anaemia occurring in 10%. Conventional treatment includes high-dose steroids. Second line agents used in refractory cases include azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide. Rituximab, anti-CD20 monoclonal antibody, is emerging in the treatment of SLE refractory to conventional therapy. We report the successful use of anti-CD20 therapy in the treatment of acute life threatening haemolytic anaemia, complicating childhood onset SLE. We propose that earlier introduction of rituximab may reduce the side effects related to other cytotoxic therapy mainly steroids and cyclophosphamide. However, in view of controversies in the reported side effects of rituximab in childhood onset SLE, multicentred randomised controlled trials are required to determine the long-term efficacy, safety and optimal dosing of rituximab in childhood onset SLE.
ACCESSION #
37219284

 

Related Articles

  • Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Murray, Eleanor; Perry, Martin // Clinical Rheumatology;Jul2010, Vol. 29 Issue 7, p707 

    Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and...

  • Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus. Karageorgas, Theofanis; Zomas, Athanasios; Kazakou, Pinelopi; Katsimbri, Pelagia; Mantzourani, Marina; Boumpas, Dimitrios // Rheumatology;Nov2016, Vol. 55 Issue 11, p2087 

    The article presents the case of a female patient suffering from severe autoimmune haemolytic anemia since the age of seven. Topics discussed include findings on medical examination of the patient, description of ofatumab, a treatment for chronic lymphocytic leukamia-associated AIHA, and...

  • Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Kotani, Takuya; Takeuchi, T.; Kawasaki, Y.; Hirano, S.; Tabushi, Y.; Kagitani, M.; Makino, S.; Hanafusa, T. // Lupus;2006, Vol. 15 Issue 10, p683 

    Cold agglutinin disease (CAD) is a rare cause of anaemia in patients with systemic lupus erythematosus (SLE). CAD is usually refractory to glucocorticosteroid, and other immunosuppressive and/or cytotoxic therapies. We report the case of a 55-years old woman with SLE and CAD that did not respond...

  • Long lasting remission by rituximab in a patient with primary cold agglutinin autoimmune haemolytic anaemia. Glaser, Marjana; Glaser, Andrej; Skalicky, Marjan // Wiener Klinische Wochenschrift;Nov2011, Vol. 123 Issue 21/22, p680 

    A 76-year-old female patient with cold agglutinin autoimmune haemolytic anaemia (CAHA) is presented. The haemolysis worsened during infection. Earlier, the patient underwent an unsuccessful treatment with steroids, chlorambucil , folic acid and heated erythrocyte transfusion. We treated her with...

  • Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Reddy, Pavan S.; Deauna-Limayo, Delva; Cook, James D.; Ganguly, Siddhartha S.; Blecke, Carol; Bodensteiner, David C.; Skikne, Barry S.; Sahud, Mervin A. // Annals of Hematology;Apr2005, Vol. 84 Issue 4, p232 

    Several reports have defined nonfamilial thrombotic thrombocytopenic purpura (TTP) as an autoimmune disorder caused by antibodies to von Willebrand’s factor-cleaving protease (vWF-CP). This raises the possibility that rituximab, a monoclonal antibody against CD20 present in B-lymphoid...

  • Treatment of thrombotic thrombocytopenic purpura. Straaten, Menno van der; Jamart, Sophie; Wens, Robert; Gottignies, Philippe; Dratwa, Max; Devriendt, Jacques // Intensive Care Medicine;Apr2005, Vol. 31 Issue 4, p600 

    This article focuses on the treatment of thrombotic thrombocytopenic purpura. The sometimes-autoimmune characteristics of thrombotic thrombocytopenic purpura (TTP) gives a rationale for treatment with Rituximab, a chimeric monoclonal antibody against the CD20 receptor of B-lymphocytes, and...

  • Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. García-Hernández, Francisco J.; González-León, Rocío; Castillo-Palma, María J.; Ocaña-Medina, Celia; Sánchez-Román, Julio // Rheumatology;Oct2012, Vol. 51 Issue 10, p1918 

    The article discusses case study of a 52-year-old woman with systemic lupus erythematosus (SLE) and autoimmune haemolytic anaemia (AIHA) resistant to glucocorticoids (GCs) and immunosuppressants. Initial treatment included administration of rituximab, followed by Deflazacort after the recurrence...

  • Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20). Eisenberg, Robert // Endocrine, Metabolic & Immune Disorders - Drug Targets;Dec2006, Vol. 6 Issue 4, p345 

    B cells play a central role in the pathogenesis of SLE. Not only do they make autoantibodies, but they can provide immunoregulatory controls of T cells, dendritic cells, and other B cells, in part through cytokine production. The availability of a chimeric monoclonal antibody that targets B...

  • Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus? Gorman, C.; Leandro, M.; Isenberg, D. // Lupus;2004, Vol. 13 Issue 5, p312 

    B celldysfunction and pathogenic autoantibodyformationarethoughtto becriticalin thepathogenesis of systemic lupus erythematosus (SLE). In this review we will summarize the results of attempts to utilize B cell depletion, based on the use of a chimeric monoclonal antibody (MAb) specific for human...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics